ArticleFrontiers in pharmacology2025
Effectiveness of Yinhua Pinggan granules in community-acquired pneumonia: a randomized, double-blind clinical trial.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nebulised Chinese herbal medicine for paediatric pneumonia: a meta-analysis.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological relevance: Community-acquired pneumonia (CAP) is an acute inflammation of the alveoli and distal bronchi caused by bacterial, viral, or other pathogenic microbial infections. Yinhua Pinggan (YHPG) granules have demonstrated anti-inflammatory, antibacterial, and antiviral effects, suggesting their potential as a treatment option for CAP. Aim: To assess the efficacy and safety of traditional Chinese medicine (TCM), YHPG granules, in combination with conventional pneumonia treatments. Materials and methods: This randomized, double-blind, placebo-controlled clinical trial was conducted at a medical center in Hangzhou and involved 240 eligible participants. In addition to conventional pneumonia treatment, participants were randomly assigned in a 1:1 ratio to receive either YHPG granules or placebo for 10 days. The primary outcome measure was the difference in pneumonia cure rates at the end of treatment. Secondary outcomes included chest CT absorption rate, criticality score (SMART-COP score), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, C-reactive protein (CRP) level, lactate (LC) level, procalcitonin (PCT) level, time for symptom recovery, length of hospital stay, and TCM syndrome scores. Results: In total, 229 participants were included in the analysis. The pneumonia cure rate in the YHPG granule group was higher than that in the placebo group (37.2% vs. 22.4%, mean difference: 14.75%, 95% CI: 3.05-26.46, Conclusion: YHPG granules are a promising adjunct therapeutic agent for CAP. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=127908, identifier ChiCTR2100047501.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.